1. Acknowledgement to referees

   ACKNOWLEDGEMENT TO REFEREES 28 October 2021 Pages: 553 - 556

2. Tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a profile of its use

   • Anthony Markham

   Adis Drug Q&A 21 October 2021 Pages: 557 - 562

3. Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a profile of its use

   • Sheridan M. Hoy

   Adis Drug Q&A 11 November 2021 Pages: 563 - 572

   

4. Educate patients with medication overuse headache, and intervene, when necessary

   • Caroline Fenton
   • Arnold Lee

   Practical Issues and Updates 10 November 2021 Pages: 573 - 578

5. What will be the role of molnupiravir in the treatment of COVID-19 infection?

   • Antonio Vitiello
   • Valentina Troiano
   • Raffaele La Porta

   Commentary 05 November 2021 Pages: 579 - 580

6. Intranasal metoclopramide for acute and recurrent diabetic gastroparesis in adults

   • Devada Singh-Franco
   • William R. Wolowich
   • Daisy De La Rosa

   Review Article 06 October 2021 Pages: 581 - 589

   

7. Language proficiency and warfarin-related adverse events in older immigrants and Canadian residents: a population-based cohort study

   • Don Thiwanka Wijeratne
   • Karen Okrainec
   • Sudeep S. Gill

   Original Research Article 10 November 2021 Pages: 590 - 598

8. Prescriber responses to alternative alert builds (AABs) designed for enduring drug shortages: a descriptive study

   • Christine M. Pujol Rooks
   • Brian Spoelhof
   • Kate Bidwell Horton

   Original Research Article 09 November 2021 Pages: 599 - 606

   

9. Correction to: Intranasal metoclopramide for acute and recurrent diabetic gastroparesis in adults

   • Devada Singh-Franco
   • William R. Wolowich
   • Daisy De La Rosa

   Correction 22 October 2021 Pages: 607 - 607